465 studies on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The widespread presence of unidentified impurities in commonly used compounded medications poses a significant patient safety risk, potentially altering the drug's efficacy, stability, or causing unforeseen adverse ef…
Successfully demonstrating the acceptability and practicality of Tirzepatide in this population is crucial. If proven feasible, this intervention could offer a vital strategy to address obesity in breast cancer surviv…
If the EXER-MED trial demonstrates that combining exercise with tirzepatide leads to significantly better outcomes than medication alone, it could redefine the standard of care for obesity management. This research ha…
This study is significant because Tirzepatide could offer a novel therapeutic strategy for managing endometrial intra-epithelial neoplasia (EIN) and early-stage endometrial cancer, particularly in obese women. Given t…
The successful completion of this Phase 1 study is a significant step forward in addressing pediatric obesity, a condition with limited pharmacological interventions. Tirzepatide, a dual GLP-1 and GIP receptor agonist…
The successful completion of this Phase 1/1b study is crucial for advancing TLC-6740 as a potential novel therapeutic agent for obesity and Type 2 Diabetes, conditions that continue to pose significant public health c…
The development of ALN-2232 represents a novel approach to treating obesity, potentially offering a new mechanism of action beyond existing therapies. If successful, this RNAi therapeutic could provide an important ne…
This study holds significant promise by exploring the potential for a novel, enhanced therapeutic approach for managing complex metabolic disorders like obesity and Type 2 Diabetes. By combining a specially formulated…
This comprehensive toxicological profile provides a crucial foundation for understanding the safety landscape of existing anti-diabetic drugs and informing the development of safer next-generation therapies. The ident…
This study highlights a crucial, previously under-recognized aspect of GLP-1RA therapy: its potential impact on male sexual health. The finding that GLP-1RAs may increase the risk of erectile dysfunction suggests that…
This research highlights a novel, non-glycemic benefit of Tirzepatide, suggesting its potential beyond glucose and weight management. The ability of Tirzepatide to significantly enhance angiogenesis and improve blood …
This study highlights a critical safety signal, suggesting that GLP-1 receptor agonists may be associated with an increased risk of depressed mood and suicidal ideation in real-world settings. This finding underscores…
This study provides crucial evidence for clinicians and patients, highlighting the distinct advantages of metabolic and bariatric surgery in achieving more profound and sustained improvements in cardiometabolic risk p…
This case highlights a potential adverse dermatological reaction to tirzepatide, suggesting that GLP-1/GIP receptor agonists might, in rare instances, trigger or exacerbate autoimmune conditions like psoriasis. This o…
This comprehensive review underscores Semaglutide's robust potential as an effective pharmacological intervention for chronic weight management in non-diabetic adults. The consistent and substantial weight loss, coupl…
These findings provide compelling evidence that tirzepatide can fundamentally alter the disease classification for a significant number of individuals with obesity and overweight, moving them into lower-risk BMI categ…
Tirzepatide not only facilitates significant weight loss but also enables a substantial proportion of individuals with obesity to achieve healthier BMI categories, which is directly associated with profound improvemen…
This review highlights Tirzepatide's potential as a valuable adjunct therapy for managing the complex challenges of Type 1 Diabetes complicated by overweight or obesity. The dual benefits of improved glycemic control …
This study is highly significant because it could establish Tirzepatide as a novel therapeutic agent for directly improving cardiovascular health in overweight and obese individuals with existing Coronary Artery Disea…
This study provides crucial dose-response data for NNC0519-0130, suggesting it could be a highly effective once-weekly treatment for Type 2 Diabetes. The observed significant reductions in HbA1c and body weight, coupl…
The findings from this study are crucial because they will inform the safe and effective use of AD109 in a growing population of OSA patients who are also managing their weight or diabetes with GLP-1 medications. If A…
Obesity is a major comorbidity in breast cancer patients, negatively impacting treatment efficacy and increasing recurrence risk. This study is significant because it directly addresses the potential of a powerful wei…
This pilot study is critically important because it addresses a significant clinical challenge: achieving healthy weight loss in older adults without compromising vital muscle and bone mass. If Tirzepatide can demonst…
This study provides compelling evidence that tirzepatide, a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, is significantly more effective than semaglutid…
This research provides compelling evidence that Tirzepatide, a dual GIP/GLP-1 receptor agonist, may offer a novel therapeutic approach to improve outcomes for obese patients after TAVR. By significantly reducing subcl…
This study provides compelling evidence that combining GLP-1 receptor agonists with progestin therapy could be a highly effective and safe fertility-sparing treatment for EIN and early-stage endometrial cancer. The si…
Improved device design, particularly through automation, can significantly enhance patient safety and adherence for chronic conditions requiring frequent self-injection, such as type 2 diabetes and obesity. Reducing c…
The systematic review identified a consistent, albeit variable, reporting of hair loss among patients receiving GLP-1 receptor agonists. Across the analyzed studies, the incidence of alopecia ranged from approximately…
This systematic review provides compelling evidence that incretin-based therapies offer superior body composition benefits, promoting greater fat loss while better preserving crucial lean muscle mass, which is vital f…
The investigation of eloralintide, particularly in combination with tirzepatide, represents a significant step in developing next-generation treatments for obesity. If eloralintide demonstrates a favorable safety and …
Understanding the drug effect of Tirzepatide on musculoskeletal abnormalities is critical for optimizing obesity treatment strategies. This research could provide evidence for the necessity of combining GLP-1 therapie…
This study is significant because it explores a novel therapeutic approach for two intertwined and devastating conditions: Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease. If successful, tirzepatid…
This feasibility study could provide crucial preliminary evidence for a novel and highly effective treatment strategy for obesity-related hypertension in a vulnerable young adult population. If successful, it could es…
This study provides crucial insights for plastic surgeons and patients, indicating that GLP-1 RA-induced weight loss may be associated with a slightly lower incidence of minor complications following body contouring s…
This study provides strong evidence that GLP-1 Receptor Agonists, exemplified by semaglutide, can directly improve cardiac function and clinical outcomes in patients with HFrEF, beyond their established metabolic bene…
This systematic review underscores the transformative potential of GLP-1 receptor agonists in the management of obesity and its associated health complications. The consistent and significant weight loss observed, cou…
This review highlights the significant potential of GLP-1 RAs as a novel adjunctive therapy for Cystic Fibrosis, offering benefits beyond their established role in diabetes management. Their pleiotropic effects could …
This research highlights that tirzepatide offers substantial cardiovascular benefits, specifically in reducing blood pressure and improving heart function, independent of its known metabolic effects. The observed modu…
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
Understanding the nuanced differences in how GLP-1 receptor agonists and gastric bypass surgery affect body composition is crucial for optimizing treatment strategies for obesity. If GLP-1 RAs can achieve similar bene…
This research is highly significant as it targets a critical unmet need in Type 2 Diabetes management: patients who do not achieve adequate glycemic control even with potent GLP-1 or GLP-1/GIP receptor agonists. LY345…
This Phase 2a study is crucial because it targets a specific genetic subtype of MASLD that is often more aggressive and difficult to treat. ALN-PNP works by reducing the PNPLA3 protein, which is implicated in liver fa…
This study provides compelling evidence that Tirzepatide offers substantial cardiovascular protection beyond its established glucose-lowering and weight-loss benefits, positioning it as a critical therapy for patients…
This study provides compelling evidence that tirzepatide, a dual GLP-1 and GIP receptor agonist, offers substantial cardiovascular protection beyond its established glycemic control and weight loss benefits in patient…
This study provides compelling evidence that Tirzepatide, a dual GIP and GLP-1 receptor agonist, significantly improves cardiovascular outcomes in patients with Type 2 Diabetes and high cardiovascular risk. This posit…